UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/674,904	09/30/2003	Cecil Kost	MMSI121562	8999	
	7590 06/09/200 N, O'CONNOR, JOHN	EXAMINER			
1420 FIFTH AVENUE			LASTRA, DANIEL		
SUITE 2800 SEATTLE, WA	x 98101-2347		ART UNIT	PAPER NUMBER	
			3688		
			MAIL DATE	DELIVERY MODE	
			06/09/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/674,904	KOST ET AL.		
Examiner	Art Unit		

	Britile Erio II Vi	0000					
The MAILING DATE of this communication appe	ars on the cover sheet with the d	correspondence add	ress				
THE REPLY FILED 28 April 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apper for Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request				
a) $\square$ The period for reply expires $3$ months from the mailing date							
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to	ater than SIX MONTHS from the mailing	g date of the final rejection	n.				
Examiner Note: If box 1 is checked, check either box (a) or ( MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount on the hortened statutory period for reply origing than three months after the mailing date.	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as				
2. The Notice of Appeal was filed on 04/28/2008. A brief in o	compliance with 37 CFR 41.37 mus	t be filed within two m	onths of the				
date of filing the Notice of Appeal (37 CFR 41.37(a)), or all Since a Notice of Appeal has been filed, any reply must be AMENDMENTS	ny extension thereof (37 CFR 41.3)	7(e)), to avoid dismiss	al of the appeal.				
3. The proposed amendment(s) filed after a final rejection, b	out prior to the date of filing a brief	will not be entered be	cause				
(a) They raise new issues that would require further cor			cause				
(b) They raise the issue of new matter (see NOTE below	•	L 50.011),					
(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or							
(d) ☐ They present additional claims without canceling a c	corresponding number of finally reig	ected claims.					
NOTE: (See 37 CFR 1.116 and 41.33(a)).	gg						
4. The amendments are not in compliance with 37 CFR 1.12	21 See attached Notice of Non-Co	mpliant Amendment (I	PTOL-324)				
5. Applicant's reply has overcome the following rejection(s):		(					
6. Newly proposed or amended claim(s) would be all non-allowable claim(s).		imely filed amendmer	nt canceling the				
7. For purposes of appeal, the proposed amendment(s): a) [ how the new or amended claims would be rejected is prov		l be entered and an ex	xplanation of				
The status of the claim(s) is (or will be) as follows: Claim(s) allowed:	та положения предоставления положения						
Claim(s) objected to:							
Claim(s) rejected: <u>1,2,4-10,16-25,31,33-45 and 51-55</u> . Claim(s) withdrawn from consideration:							
AFFIDAVIT OR OTHER EVIDENCE							
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>							
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	al and/or appellant fails	s to provide a				
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attache	ed.				
11. The request for reconsideration has been considered but See Continuation Sheet.	t does NOT place the application in	condition for allowand	ce because:				
12. Note the attached Information Disclosure Statement(s). (	PTO/SB/08) Paper No(s)						
13. Other:							
	/Raquel Alvarez/ Primary Examiner, Art U	nit 3688					
	i iiiiaiy Laiiiiiei, Aft U	THE 3000					

Continuation of 11. does NOT place the application in condition for allowance because: The Applicant argues that because the Office requires the same words to appear in the specification to support claim limitation, the Office has failed, according to the Applicant, to state a proper 112 rejection. The Examiner answers that Applicant's specification only mentions the term "brand website" in Applicant's specification page 7 where it recites "many other personalizations capabilities to tailor the distribution of drug samples to prescribers are possible, such as brand website". Applicant's specification does not mention anything else with respect to brand website. Peyrelevade teaches customizing the products presented to a user browsing a website based upon said website branding (see paragraphs 51-52). Therefore, contrary to Applicant's argument, Peyrelevade teaches Applicant's claimed limitation. The Applicant argues that it is a bizarre interpretation that lipstick or other beauty products can be construed as drug samples. The Examiner answers that Peyrelevade was used by the Examiner to simply teach that it is old and well known in the promotion art to customize the products presented to a user browsing a website based upon the brand of said website. Therefore, Peyrelevade is relevant to Applicant's claimed invention.